Recent News

• 01.29.2026 - Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
• 01.06.2026 - Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
• 01.05.2026 - Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
• 12.18.2025 - Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
• 12.09.2025 - Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
• 12.04.2025 - Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

Recent Filings

• 01.14.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - 144 Report of proposed sale of securities
• 01.09.2026 - 144 Report of proposed sale of securities
• 01.09.2026 - 144 Report of proposed sale of securities
• 01.06.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.05.2026 - EX-99.1 EX-99.1
• 01.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.18.2025 - EX-99.1 EX-99.1